These results confirmed our prediction of the master regulators in the mTOR-PI3K signaling pathway responsible for the elevated resistance of particular lung cancer cell lines to treatment by the p53-reactivating compound Nutlin-3. The gene discussed is MTOR; the disease is lung carcinoma.